Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases." (6/24/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >
"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older." (6/17/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >
"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better." (6/17/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Joe Pantginis More >
Brian Bloom is a cofounder of Bloom Burton & Co. and serves as the firm's president and head of institutional sales and capital market activities. By forging unique relationships with international healthcare-specialized investors, Bloom attracts capital for growing companies seeking to accelerate returns for investors. Before co-founding Bloom Burton, Bloom spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. Earlier in his career, he spent two years in the equity research group at a New York-based merchant banking firm, SCO Group, and was an investment banking analyst at M&A advisory firm, Molecular Securities. Bloom is a member of the Life Sciences Advisory Board at the National Research Council of Canada and the Board of Directors at BIOTECanada. Bloom received an bachelor's degree with honors in biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University with a focus in molecular endocrinology and biophysics.
Stunning Potential for Upside in Canadian Biotech: Brian Bloom (6/12/14) You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling skill sets and pipelines. In this interview with The Life Sciences Report, Bloom talks about his firm's upcoming conference and presents a detailed picture of four very interesting companies that could return doubles, triples or more.
"CYNA is now well funded, NASDAQ-listed and liquid; it isdefinitely among my better ideas as of today." (7/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >
"BCLI has what looks to be a safe and potentially effective treatment for delaying disease progression in patients with ALS." (7/8/15) BrainStorm Cell Therapeutics Inc. - The Life Sciences Report Interview with Jason Napodano More >
"If results from RVX's Phase 3 program are positive, the stock could have a significant revaluation to much higher levels." (7/8/15) Resverlogix Corp. - The Life Sciences Report Interview with Jason Napodano More >